tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Thomas Shrader, 96 are a BUY (89.72%), 11 are a HOLD (10.28%).
Analyst Thomas Shrader, currently employed at BTIG, carries an average stock price target met ratio of 45.47% that have a potential upside of 43.51% achieved within 199 days.
Thomas Shrader’s has documented 213 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BHVN, Biohaven Pharmaceutical Holding Co Ltd at 09-Jan-2024.
Analyst best performing recommendations are on SLN (SILENCE THERAPEUTICS PLC).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC ADR) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$45
$21.99 (95.57%)
$44
5 days ago
(15-Nov-2024)
3/5 (60%)
$21.99 (95.57%)
220
Buy
$43
$19.99 (86.88%)
$43
26 days ago
(25-Oct-2024)
6/24 (25%)
$19.16 (80.37%)
327
Buy
$46
$22.99 (99.91%)
$48
1 months 3 days ago
(17-Oct-2024)
12/17 (70.59%)
$19.81 (75.64%)
294
Buy
$70
$46.99 (204.22%)
$70
2 months 4 days ago
(16-Sep-2024)
1/8 (12.5%)
$43.81 (167.28%)
244
Buy
$42
$18.99 (82.53%)
$42
2 months 9 days ago
(11-Sep-2024)
2/5 (40%)
$14.01 (50.05%)
46
What Year was the first public recommendation made by Thomas Shrader?
